XM اپنی سروسز امریکہ کے شہریوں کو فراہم نہیں کرتا ہے۔
N
N

Novartis


خبر

Novartis Novartis Kisqali® Shows Deepening Benefit In New Analysis, Reducing Risk Of Recurrence By 28.5% In A Broad Population Of Patients With Early Breast Cancer

BRIEF-Novartis Novartis Kisqali® Shows Deepening Benefit In New Analysis, Reducing Risk Of Recurrence By 28.5% In A Broad Population Of Patients With Early Breast Cancer Novartis AG NOVN.S : : NOVARTIS KISQALI® SHOWS DEEPENING BENEFIT IN NEW ANALYSIS, REDUCING RISK OF RECURRENCE BY 28.5% IN A BROAD POPULATION OF PATIENTS WITH EARLY BREAST CANCER
N

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds price and availability in paragraph 4 Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R

US FDA approves injectable version of Roche's multiple sclerosis therapy

US FDA approves injectable version of Roche's multiple sclerosis therapy Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R

BMW, Legrand, Sodexo

EUROPE RESEARCH ROUNDUP- BMW, Legrand, Sodexo Sept 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including BMW, Legrand and Sodexo, on Wednesday. HIGHLIGHTS * BMW BMWG.DE : HSBC cuts target price to EUR 85 from EUR 109 * Kion Group AG KGX.DE : JP Morgan raises to overweight from neutral * Legrand LEGD.PA : JP Morgan raises to overweight from neutral * Phoenix PHNX.L : Peel Hunt cuts target price to 650p from 690p * Sodexo EXHO.PA : JP M
A
A
A
A
B
C
E
E
E
G
I
K
L
L
M
N
P
R
S
S
T
U
V
W
E

Relay Therapeutics' combo therapy cuts breast cancer progression in early study

UPDATE 1-Relay Therapeutics' combo therapy cuts breast cancer progression in early study Adds shares in paragraph 1 By Mariam Sunny and Sneha S K Sept 9 (Reuters) - Relay Therapeutics RLAY.O said on Monday interim data from an early-stage study of its combination drug for breast cancer showed it meaningfully extended the time patients lived without the disease worsening, sending shares surging about 37% in early trading.
A
N

Relay Therapeutics' combo therapy for breast cancer cuts disease progression in early study

Relay Therapeutics' combo therapy for breast cancer cuts disease progression in early study By Mariam Sunny and Sneha S K Sept 9 (Reuters) - Relay Therapeutics RLAY.O said on Monday interim data from an early-stage study of its experimental combination treatment for breast cancer showed it meaningfully extended the time patients lived without their disease worsening.
A
N

Judge won't block Maryland law mandating discounts for hospitals' outside pharmacies

Judge won't block Maryland law mandating discounts for hospitals' outside pharmacies By Brendan Pierson Sept 6 (Reuters) - The largest U.S. drug industry group and several drug companies have lost a bid to block a Maryland law requiring drugmakers to offer discounts on drugs dispensed by third-party pharmacies that contract with hospitals and clinics serving low-income populations.
A
N

U.S. STOCKS MarketAxess, Perpetua Resources, Sotera Health

BUZZ-U.S. STOCKS ON THE MOVE-MarketAxess, Perpetua Resources, Sotera Health Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's three main indexes slipped in choppy trading on Thursday as a short-lived boost from a services activity survey fizzled out ahead of an upcoming employment report.
J
N
N
T
V
U
D
U
U
M
S
Z
F

U.S. STOCKS Hoth Therapeutics, gold miners, Gatos Silver

BUZZ-U.S. STOCKS ON THE MOVE-Hoth Therapeutics, gold miners, Gatos Silver Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Futures tied to the S&P 500 pared some losses after a less-than-expected rise in weekly jobless claims calmed some worries over a cooling labor market.
J
N
T
V
U
U
S
F

Voyager climbs on expanded licensing deal with Novartis

BUZZ-Voyager climbs on expanded licensing deal with Novartis ** Shares of biotech company Voyager Therapeutics VYGR.O rise ~4.8% to $6.50 premarket ** VYGR says Novartis AG NOVN.S has agreed to license a capsid or gene therapy delivery vehicle, generated from Voyager's RNA-based screening platform TRACER capsid ** The capsid will be used against an
N

Voyager Enters Into License For Next-Generation Capsid, Bringing Partnered Portfolio Of Tracer-Enabled Gene Therapies To 14

BRIEF-Voyager Enters Into License For Next-Generation Capsid, Bringing Partnered Portfolio Of Tracer-Enabled Gene Therapies To 14 Novartis AG NOVN.S : VOYAGER ENTERS INTO LICENSE FOR NEXT-GENERATION CAPSID, BRINGING PARTNERED PORTFOLIO OF TRACER-ENABLED GENE THERAPIES TO 14 VOYAGER THERAPEUTICS: TO GET $15M UPFRONT, ELIGIBLE TO GET UP TO $305 MILLI
N

GS cuts Novartis to 'neutral' on limited catalysts over the next year

BUZZ-GS cuts Novartis to 'neutral' on limited catalysts over the next year ** Goldman Sachs cuts Swiss drugmaker Novartis NOVN.S to "neutral" from "buy" on limited catalysts after a strong run of the shares and earlier-than-expected upgrades to consensus ** The stock is up around 18% YTD at CHF 100, vs GS's lowered PT of CHF 103, after two guidance
N

Air Liquide, Novo Nordisk, Syensqo

EUROPE RESEARCH ROUNDUP- Air Liquide, Novo Nordisk, Syensqo Sept 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Air Liquide, Novo Nordisk and Syensqo, on Thursday. HIGHLIGHTS * Air Liquide AIRP.PA : Morgan Stanley cuts to underweight from equal-weight * Lanxess AG LXSG.DE : Morgan Stanley raises to overweight from underweight * Novo Nordisk NOVOb.CO : JP Morgan raises target price to DKK 1050 from DKK 950 * Swiss Life Holding AG
A
A
A
A
B
B
C
E
K
L
N
W
A
A
A
S
S

Novartis begins construction of two new radioligand therapy facilities in the US

BRIEF-Novartis begins construction of two new radioligand therapy facilities in the US Sept 4 (Reuters) - Novartis AG NOVN.S : NOVARTIS BEGINS CONSTRUCTION OF TWO NEW RADIOLIGAND THERAPY FACILITIES IN THE US, EXPANDING ITS WORLD-CLASS RLT MANUFACTURING AND SUPPLY NETWORK Source text for Eikon: ID:nPn9fJJNSa Further company coverage: NOVN.S
N

European companies cut jobs as economy sputters

FACTBOX-European companies cut jobs as economy sputters Adds Telia Sept 4 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some of the layoffs announced since the start of April: BANKS * TSB: The British bank owned by Spain's Sabadell SABE.MC is seeking 250 job cuts, its spokesperson and employee union said on May 8. INDUSTRIALS AND ENGINEERING * PKP CARGO PKPP.WA : Poland's largest freight co
B
B
B
C
I
N
T
T
U
V
B
U

US will still pay at least twice as much after negotiating drug prices

UPDATE 1-US will still pay at least twice as much after negotiating drug prices U.S. pays higher drug prices, gets priority access Medicare's negotiated prices most significant for drugs with little competition Goal is to balance affordability and innovation Updates first graphic to align colors representing countries with second graphic By Deena Beasley Sept 3 (Reuters) - The U.S.
A
A
B
N
P

Jefferies cuts Novartis to 'hold' on lack of mid-term catalysts

BUZZ-Jefferies cuts Novartis to 'hold' on lack of mid-term catalysts ** Jefferies cuts Swiss drugmaker Novartis NOVN.S to "hold" from "buy", citing lack of mid-term catalysts after the recent upgrade cycle ** The brokerage notes the stock is up more than 20% YTD ** It will take time into 2025 for approvals & ramp-ups to drive wider optimism in traj
N

Top of the Street: BMW, Volkswagen, OMV, IMCD, Barratt, Novartis

BUZZ-Top of the Street: BMW, Volkswagen, OMV, IMCD, Barratt, Novartis A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Exane BNP Paribas cuts BMW BMWG.DE to "neutral" from "outperform" and raises Volkswagen VOWG_p.DE to "outperform" from "neutral" citing the need for strong product flow and cost action as the automotive industry faces a new deflationary era, with premium mix peaking and growth increasingly reliant on emerging markets ** UBS raises Austria
B
B
N
O
P
V



شرائط

مشہور اثاثے

دستبرداری: XM Group کے ادارے ہماری آن لائن تجارت کی سہولت تک صرف عملدرآمد کی خدمت اور رسائی مہیا کرتے ہیں، کسی شخص کو ویب سائٹ پر یا اس کے ذریعے دستیاب کانٹینٹ کو دیکھنے اور/یا استعمال کرنے کی اجازت دیتا ہے، اس پر تبدیل یا توسیع کا ارادہ نہیں ہے ، اور نہ ہی یہ تبدیل ہوتا ہے یا اس پر وسعت کریں۔ اس طرح کی رسائی اور استعمال ہمیشہ مشروط ہوتا ہے: (i) شرائط و ضوابط؛ (ii) خطرہ انتباہات؛ اور (iii) مکمل دستبرداری۔ لہذا اس طرح کے مواد کو عام معلومات سے زیادہ کے طور پر فراہم کیا جاتا ہے۔ خاص طور پر، براہ کرم آگاہ رہیں کہ ہماری آن لائن تجارت کی سہولت کے مندرجات نہ تو کوئی درخواست ہے، اور نہ ہی فنانشل مارکیٹ میں کوئی لین دین داخل کرنے کی پیش کش ہے۔ کسی بھی فنانشل مارکیٹ میں تجارت میں آپ کے سرمائے کے لئے ایک خاص سطح کا خطرہ ہوتا ہے۔

ہماری آن لائن تجارتی سہولت پر شائع ہونے والے تمام مٹیریل کا مقصد صرف تعلیمی/معلوماتی مقاصد کے لئے ہے، اور اس میں شامل نہیں ہے — اور نہ ہی اسے فنانشل، سرمایہ کاری ٹیکس یا تجارتی مشورے اور سفارشات؛ یا ہماری تجارتی قیمتوں کا ریکارڈ؛ یا کسی بھی فنانشل انسٹرومنٹ میں لین دین کی پیشکش؛ یا اسکے لئے مانگ؛ یا غیر متنازعہ مالی تشہیرات پر مشتمل سمجھا جانا چاہئے۔

کوئی تھرڈ پارٹی کانٹینٹ، نیز XM کے ذریعہ تیار کردہ کانٹینٹ، جیسے: راۓ، خبریں، تحقیق، تجزیہ، قیمتیں اور دیگر معلومات یا اس ویب سائٹ پر مشتمل تھرڈ پارٹی کے سائٹس کے لنکس کو "جیسے ہے" کی بنیاد پر فراہم کیا جاتا ہے، عام مارکیٹ کی تفسیر کے طور پر، اور سرمایہ کاری کے مشورے کو تشکیل نہ دیں۔ اس حد تک کہ کسی بھی کانٹینٹ کو سرمایہ کاری کی تحقیقات کے طور پر سمجھا جاتا ہے، آپ کو نوٹ کرنا اور قبول کرنا ہوگا کہ یہ کانٹینٹ سرمایہ کاری کی تحقیق کی آزادی کو فروغ دینے کے لئے ڈیزائن کردہ قانونی تقاضوں کے مطابق نہیں ہے اور تیار نہیں کیا گیا ہے، اسی طرح، اس پر غور کیا جائے گا بطور متعلقہ قوانین اور ضوابط کے تحت مارکیٹنگ مواصلات۔ براہ کرم یقینی بنائیں کہ آپ غیر آزاد سرمایہ کاری سے متعلق ہماری اطلاع کو پڑھ اور سمجھ چکے ہیں۔ مذکورہ بالا معلومات کے بارے میں تحقیق اور رسک وارننگ ، جس تک رسائی یہاں حاصل کی جا سکتی ہے۔

خطرے کی انتباہ: آپکا سرمایہ خطرے پر ہے۔ ہو سکتا ہے کہ لیورج پروڈکٹ سب کیلیے موزوں نہ ہوں۔ براہ کرم ہمارے مکمل رسک ڈسکلوژر کو پڑھیے۔